Zacks Investment Research Downgrades INDIVIOR PLC/S (INVVY) to Sell
INDIVIOR PLC/S (OTCMKTS:INVVY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
A number of other analysts also recently weighed in on the stock. Jefferies Financial Group downgraded shares of INDIVIOR PLC/S from a “buy” rating to a “hold” rating in a research report on Wednesday, November 21st. ValuEngine downgraded shares of INDIVIOR PLC/S from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 21st.
INDIVIOR PLC/S (OTCMKTS:INVVY) last issued its quarterly earnings data on Thursday, November 1st. The company reported $0.40 earnings per share (EPS) for the quarter. The company had revenue of $245.00 million for the quarter. As a group, sell-side analysts expect that INDIVIOR PLC/S will post 1.7 EPS for the current fiscal year.
About INDIVIOR PLC/S
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Featured Story: What impact do institutional investors have on markets?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.